Roche Reports the Acquisition of Telavant along with its Asset RVT-3101 from Roivant for the Treatment of Inflammatory Bowel Disease
- As per the agreement, Telavant will receive an up front of $7.1B & a near-term milestone payment of $150M whereas Roche received further development & manufacturing rights for RVT-3101 (TL1A inhibitor)
- Roche is responsible for the commercialization of RVT-3101 across the US & Japan post-pending clinical & regulatory success & initiating the global P-III clinical trial for RVT-3101 to treat IBD. Additionally, Pfizer is responsible for the commercialization of RVT-3101 in areas outside the US & Japan
- Post-closing of the transaction (expected by Q4’23 or Q1’24), Roche will have the option to enter into a global collaboration with Pfizer for next-generation p40/ TL1A directed bispecific Ab in P-I clinical trial
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.